Rexahn Pharmaceuticals to Present at the Bio 2009 International Convention

Download as PDF

ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage biopharmaceutical company developing first-in-class oncology and CNS therapeutics, today announced that it will present at the BIO 2009 International Convention at the Georgia World Congress Center (Room 314, Building A, Level 3) in Atlanta, GA on Wednesday, May 20, 2009 at 3:00 PM ET.

Rexahn's Senior Business Development Director, Wendy Tsai, and Chief Business Officer, Rick Soni, will provide a strategic business update of Rexahn's recent clinical and financing milestones, opportunities for licensing and alliances, and an overview of its R&D pipeline.

Rexahn currently has three drug candidates in Phase II clinical trials - Archexin, Serdaxin, and Zoraxel - all potential best in class therapeutics, and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders.

If you plan on attending the conference, and would like to arrange a one-on-one meeting with management, please contact Wendy Tsai at 240-268-5300 x314.

About the BIO 2009 International Convention

Occurring May 18-21, 2009 in Atlanta, GA, the annual BIO (Biotechnology Industry Organization) conference is considered to be a premiere global event for the biopharmaceutical industry. Over 20,000 Biotechnology industry innovators, business leaders, and decision makers from 60 or more countries will connect and meet, and showcase the biotechnology industry and its global impact. http://convention.bio.org/

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn also has key R&D programs in cancer nano-medicines and multi-target aimed ligands drug discovery technologies. For more information, please visit www.rexahn.com. 


    Source: Rexahn Pharmaceuticals, Inc.

Released May 11, 2009